Ajinomoto (2802) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
30 Jun, 2026Executive summary
Sales, business profit, and profit attributable to owners reached new record highs for the first three quarters of FY2025, with strong acceleration in the third quarter and robust performance in both domestic and overseas markets.
Upward revisions were made to full-year forecasts for business profit and profit attributable to owners, driven by strong segment performance and gains from asset sales.
Strategic focus for FY2026 includes accelerating growth in Bio & Fine Chemicals and achieving 2030 Roadmap targets ahead of schedule.
Financial highlights
Cumulative Q3 FY2025 sales reached ¥1,164.1 billion (101% YoY), business profit ¥145.9 billion (105% YoY), and profit attributable to owners ¥89.7 billion (108% YoY).
Q3 FY2025 sales were ¥425.2 billion (104% YoY), business profit ¥59.2 billion (115% YoY), and profit attributable to owners ¥38.5 billion (119% YoY).
FY2025 revised full-year forecast: sales ¥1,600 billion (104% YoY), business profit ¥181 billion (113% YoY), profit attributable to owners ¥130 billion (184% YoY).
Gross profit for the nine months was ¥445.4 billion, up from ¥422.0 billion year-over-year.
Basic earnings per share increased to ¥91.82 from ¥81.54 year-over-year.
Outlook and guidance
Full-year FY2025 business profit and profit attributable to owners are revised upward, with sales forecast slightly reduced due to currency effects and lower expectations in some segments.
FY2026 targets include continued growth in Seasonings and Foods and dramatic expansion in Bio & Fine Chemicals.
The company aims to achieve its 2030 roadmap targets ahead of schedule, focusing on sustainable growth in core segments and targeting approximately 3x EPS versus FY2022 and ROE of approximately 17%.
Latest events from Ajinomoto
- Record sales and profit growth led to upward forecasts and increased shareholder returns.2802
Q2 20251 Jul 2026 - Global leader in amino acid science targets growth, health impact, and major sustainability gains.2802
Investor presentation30 Jun 2026 - AI-driven semiconductor growth boosts ABF™ demand, with major investments in capacity and innovation.2802
Investor update30 Jun 2026 - Record profit and sales growth achieved, with further gains targeted amid managed global risks.2802
Q4 202613 May 2026 - Integrated sustainability and agri-food innovation drive growth and aim to double key solution sales by 2030.2802
Investor Day 20266 May 2026 - Governance, compensation, and management reforms drive long-term growth and value creation.2802
Investor update9 Apr 2026 - Record Q1 sales and profit, but net profit fell 12% due to a temporary tax impact.2802
Q1 20252 Feb 2026 - Record sales and profit growth led by overseas, healthcare, and currency gains amid cost pressures.2802
Q3 20259 Jan 2026 - Profit attributable to owners rose 2% as H1 results were flat, with strong H2 recovery expected.2802
Q2 202610 Dec 2025